|

Prednisone, Olverembatinib, Blinatumomab, Chidamide Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Nanfang Hospital, Southern Medical University1

Indications

  • IKZF1 Gene Mutation1
  • Adult ALL1
  • Philadelphia-Positive ALL1
  • Philadelphia Chromosome1
  • Acute Lymphoblastic Leukemia1

Other1 trial

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.